Motor lumbosacral radiculopathy in HIV-infected patients.
ART
HIV
corticosteroids
lumbosacral radiculopathy
treatment outcome
Journal
Southern African journal of HIV medicine
ISSN: 2078-6751
Titre abrégé: South Afr J HIV Med
Pays: South Africa
ID NLM: 100965417
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
06
2019
accepted:
31
07
2019
entrez:
21
11
2019
pubmed:
21
11
2019
medline:
21
11
2019
Statut:
epublish
Résumé
This study is a review of the clinical findings and treatment outcome of 11 HIV-infected patients with motor lumbosacral radiculopathy. To describe the clinical, laboratory, electrophysiological features and treatment outcome in HIV-infected motor lumbosacral radiculopathy which is a rare manifestation of HIV. A retrospective review of HIV-infected patients with motor lumbosacral radiculopathy was performed at Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa between 2010 and 2015. Eleven black African patients met the inclusion criteria. There were six women. The median age was 29 years, the interquartile range (IQR) was 23-41 years, the median duration of symptom progression was 6.5 months (IQR 3-7.5 months). The median CD4 count was 327 cells/µL (IQR 146-457). The cerebrospinal fluid (CSF) median polymorphocyte count was 0 cells/µL (IQR 0 cells/µL - 2 cells/µL), lymphocyte count was 16 cells/µL (IQR 1 cells/µL - 18 cells/µL), glucose level was 3.1 mmol/L (IQR 2.8 mmol/L - 3.4 mmol/L) and protein level was 1.02 g/dL (IQR 0.98 g/dL - 3.4 g/dL). All patients were treated with corticosteroid therapy. Ninety-one per cent recovered fully within 6 months of treatment, the median time for recovery was 3.4 months (IQR 1.8-5.6 months). There were no relapses during the 18-month follow-up. HIV-infected patients with motor lumbosacral radiculopathy responded to corticosteroids, with no relapses during the 18-month follow-up period.
Sections du résumé
BACKGROUND
BACKGROUND
This study is a review of the clinical findings and treatment outcome of 11 HIV-infected patients with motor lumbosacral radiculopathy.
OBJECTIVES
OBJECTIVE
To describe the clinical, laboratory, electrophysiological features and treatment outcome in HIV-infected motor lumbosacral radiculopathy which is a rare manifestation of HIV.
METHOD
METHODS
A retrospective review of HIV-infected patients with motor lumbosacral radiculopathy was performed at Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa between 2010 and 2015.
RESULTS
RESULTS
Eleven black African patients met the inclusion criteria. There were six women. The median age was 29 years, the interquartile range (IQR) was 23-41 years, the median duration of symptom progression was 6.5 months (IQR 3-7.5 months). The median CD4 count was 327 cells/µL (IQR 146-457). The cerebrospinal fluid (CSF) median polymorphocyte count was 0 cells/µL (IQR 0 cells/µL - 2 cells/µL), lymphocyte count was 16 cells/µL (IQR 1 cells/µL - 18 cells/µL), glucose level was 3.1 mmol/L (IQR 2.8 mmol/L - 3.4 mmol/L) and protein level was 1.02 g/dL (IQR 0.98 g/dL - 3.4 g/dL). All patients were treated with corticosteroid therapy. Ninety-one per cent recovered fully within 6 months of treatment, the median time for recovery was 3.4 months (IQR 1.8-5.6 months). There were no relapses during the 18-month follow-up.
CONCLUSION
CONCLUSIONS
HIV-infected patients with motor lumbosacral radiculopathy responded to corticosteroids, with no relapses during the 18-month follow-up period.
Identifiants
pubmed: 31745432
doi: 10.4102/sajhivmed.v20i1.992
pii: HIVMED-20-992
pmc: PMC6852262
doi:
Types de publication
Journal Article
Langues
eng
Pagination
992Informations de copyright
© 2019. The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Références
JMM Case Rep. 2017 Sep 1;4(8):e005107
pubmed: 29026634
Neurology. 1987 May;37(5):888
pubmed: 3033548
Mayo Clin Proc. 2006 Feb;81(2):213-9
pubmed: 16471077
J Neurol Sci. 2019 Feb 15;397:96-102
pubmed: 30597421
Curr Opin Neurol. 1998 Dec;11(6):633-7
pubmed: 9870129
Clin Infect Dis. 2018 Jun 18;67(1):89-98
pubmed: 29340585
Rev Neurol (Paris). 2011 Apr;167(4):337-42
pubmed: 21440277
Leuk Lymphoma. 2008 Oct;49(10):2009-11
pubmed: 18720211
J Neurol Neurosurg Psychiatry. 1996 Nov;61(5):456-60
pubmed: 8937337
Neurology. 2014 Jun 3;82(22):1984-9
pubmed: 24808021
N Engl J Med. 1992 Apr 23;326(17):1130-6
pubmed: 1552914
J Neurol. 1988 Jul;235(6):359-61
pubmed: 3171617
Neurol Neuroimmunol Neuroinflamm. 2016 Dec 15;4(2):e315
pubmed: 28054000
J Clin Neuromuscul Dis. 2011 Dec;13(2):68-84
pubmed: 22361691
J Neurol Neurosurg Psychiatry. 1999 May;66(5):658-61
pubmed: 10209182
Lancet Neurol. 2013 Mar;12(3):295-309
pubmed: 23415569
PLoS One. 2008 Apr 16;3(4):e1971
pubmed: 18414666
J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii43-50
pubmed: 15146039
Sci Rep. 2015 Sep 10;5:13931
pubmed: 26355080
Arch Neurol. 2000 Jul;57(7):1034-9
pubmed: 10891986
J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):232-3
pubmed: 21205983
Neurology. 2010 Jul 13;75(2):194-5
pubmed: 20625176
J Neurol Sci. 2016 Apr 15;363:39-42
pubmed: 27000218
Cochrane Database Syst Rev. 2016 Oct 24;10:CD001446
pubmed: 27775812
Case Rep Infect Dis. 2011;2011:972096
pubmed: 22567484
Muscle Nerve. 2002 Jan;25(1):106-10
pubmed: 11754193
J Neurol Sci. 2003 Apr 15;208(1-2):39-42
pubmed: 12639723